Skip to Content

CAR-T Cell Therapy as Second-Line Treatment for Elderly Patients with Relapsed/Refractory Large B-Cell Lymphoma

Mats Jerkeman discusses in this MEDtalk the ZUMA-7 trial’s subgroup analysis from the ASH meeting. This trial compared CAR-T cell treatment to standard autologous stem cell transplant in first relapse diffuse large B-cell lymphoma (R/R LBCL) elderly patients (above 65, including those over 70). Zuma-7 shows that CAR-T cell therapy significantly improved progression-free and overall survival in this subgroup. This finding suggests CAR-T cell therapy as a viable second-line treatment for elderly R/R LBCL patients.

Mats Jerkeman

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top